This further indicates that the plasma levels of GFAP, NfL, and p-tau181 demonstrate superior performance compared to plasma Aβ1–42 and Aβ1–40 levels and the Aβ1–42/Aβ1–40 ratio in the context of cognitive impairment. The gene discussed is GFAP; the disease is Cognitive impairment.